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similar treatments for all radiation-managed patients with high-risk disease.
Methods and Materials: We studied 3618 patients with cT1-T3aN0M0 high-risk or
unfavorable intermediate-risk prostate adenocarcinoma treated with radiation at a sin-
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and PSA <10 ng/mL or
Gleason 6 and PSA
>20 ng/mL. This subset has
better outcomes than others
with high-risk disease and
similar outcomes as those
with unfavorable
intermediate-risk disease.
These results might be used
to individualize the duration
of androgen deprivation
therapy for high-risk prostate
cancer patients.determine differences in the risk of prostate cancerespecific mortality (PCSM) after
controlling for baseline factors and treatment. Our results were validated in a cohort
of 13,275 patients using the Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database.
Results: Patients with favorable high-risk disease had significantly better PCSM than
other men with high-risk disease (adjusted hazard ratio [AHR] 0.42, 95% confidence
interval [CI] 0.18-0.996, PZ.049) and similar PCSM as men with unfavorable
intermediate-risk disease (AHR 1.17, 95% CI 0.50-2.75, PZ.710). We observed very
similar results within the SEER-Medicare cohort (favorable high-risk vs other high-
risk: AHR 0.21, 95% CI 0.11-0.41, P<.001; favorable high-risk vs unfavorable
intermediate-risk: AHR 0.67, 95% CI 0.33-1.36, PZ.268).
Conclusions: Patients with favorable high-risk prostate cancer have significantly bet-
ter PCSM than other patients with high-risk disease and similar PCSM as those with
unfavorable intermediate-risk disease, who are typically treated with shorter-course
androgen deprivation therapy. This new classification system may allow for personal-
ization of treatment within high-risk disease, such as consideration of shorter-course
androgen deprivation therapy for favorable high-risk disease.  2015 The Authors.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Patients with prostate cancer are generally considered to
have high-risk disease if they have a serum prostate-specific
antigen (PSA) level of >20 ng/mL, Gleason score 8 to 10,
or clinical stage T3a (1-3). Local therapy typically consists
of radical prostatectomy or radiation therapy, and patients
may be treated with neoadjuvant, concurrent, or adjuvant
androgen deprivation therapy (ADT) (1). Based on the re-
sults of randomized trials (4-6), current guidelines recom-
mend similar treatment for all radiation-managed patients
with high-risk disease, including long-course (2 to 3 years)
ADT (1, 2). On the other hand, short-course (4-6 months)
ADT is considered standard for radiation-managed patients
with intermediate-risk disease (1, 7).
Although ADT has been shown to prolong cancer-
specific and overall survival in randomized trials, it has
also been associated with significant toxicity, such as weight
gain, decreased libido, fatigue, acute kidney injury, psychi-
atric illness, diabetes, and possibly an increased risk of
cardiovascular events (8-10). Therefore, it is desirable to
identify patients with high-risk disease who might be
adequately treated with a shorter course of ADT than is
typically recommended for this risk group. Conversely,
because there is increasing interest in trials of novel systemic
agents for high-risk prostate cancer, it would be useful to
limit enrollment to subsets of high-risk patients who might
be able to derive the most benefit from additional therapy.
Although the randomized trials that established 2 to
3 years of ADT as standard included mostly patients with
cT3 or T4 disease, stage T1c (PSA-detected) is currently
the most commonly detected form of prostate cancer (11),
and many patients with high-risk disease are diagnosed
with only 1 high-risk feature (12). In this study we used an
institutional cohort to determine whether the subset of high-risk patients with nonpalpable prostate cancer (T1c) and
either Gleason 4 þ 4Z 8 disease or PSA >20 ng/mL (but
not both) represent a favorable subset. We excluded pa-
tients with any Gleason grade 5 disease, including patients
with Gleason score 5 þ 3Z 8, 3 þ 5Z 8, or 9 to 10, from
this potentially favorable subset of patients owing to their
significantly worse outcomes in prior work (13). We vali-
dated our findings within a large, national cohort linked to
Medicare insurance claims data.
Methods and Materials
Patient population
We studied 3618 men with N0M0 prostate adenocarcinoma
who were consecutively treated with brachytherapy with or
without supplemental external beam radiation therapy
(EBRT) at a single institution between 1997 and 2013 and
were deemed to have unfavorable intermediate-risk or high-
risk prostate cancer according to consensus guidelines (1)
and the definitions described recently by Zumsteg et al
(14). Specifically, patients were considered to have high-risk
disease if they had stage T3a disease, Gleason score 8 to 10,
or PSA >20 ng/mL (1). Favorable high-risk disease was
defined as stage T1c with Gleason 4 þ 4 Z 8 and PSA
<10 ng/mL or stage T1c with Gleason 6 and PSA >20 ng/
mL. Per the Zumsteg definition, patients were considered to
have unfavorable intermediate-risk disease if they had
intermediate-risk disease (T2b-c, Gleason score 7, or PSA
10-20 ng/mL with no high-risk features) with more than 1
intermediate-risk feature, primary Gleason pattern 4, or
percentage of positive biopsy cores 50% (14). Patients
received ultrasound-guided brachytherapy with preloaded
isotopes and preplanned dosimetry. When patients were
treated with brachytherapy alone, the doses were 144 Gy
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patients were treated with combination therapy, the EBRT
dose was 45 Gy to the prostate and seminal vesicles, and the
brachytherapy boost dose was 108 Gy (iodine), 90 Gy
(palladium), or 100 Gy (cesium). This population comprised
our derivation cohort. Androgen deprivation therapy was
given at the discretion of the treating clinician for a median
duration of 4 months (interquartile range, 3-6 months) and
consisted of a luteinizing hormoneereleasing hormone
agonist with or without an antiandrogen.
To validate our findings, we also identified a national
cohort of radiation-managed prostate cancer patients with
unfavorable intermediate- or high-risk disease from the
Surveillance, Epidemiology, and End Results (SEER)
database linked with Medicare claims data. The SEER-
Medicare dataset combines patient data regarding cancer
diagnostic information and outcomes from 18 SEER cancer
registries covering 28% of the US population with admin-
istrative data for patients enrolled in Medicare (15, 16).
Because of limitations in the availability of data within
SEER, we could not include percentage of positive biopsy
cores when determining whether patients had favorable or
unfavorable intermediate-risk disease. Otherwise, the defi-
nitions for risk stratification match the definitions used by
consensus guidelines (1) and described by Zumsteg et al
(14). Because of recently reported possible inaccuracies in
the recording of PSA in the SEER database, in which some
values may have had a misplaced decimal point (17, 18),
we excluded 588 of 13,863 initial patients (4.2%) who had
discordant values for PSA and PSA interpretation (eg PSA
<4.0 ng/mL recorded as “positive/elevated” or PSA
>4.0 ng/mL recorded as “negative/normal”), giving us a
final cohort size of 13,275. This approach to identifying
possibly incorrectly coded PSA values was based on the
observations of Schymura et al (19). Using Medicare
claims data, we determined which patients in the SEER
database received ADT (codes C9216, C9430, J0128,
J1950, J9202, J1675, J9217-19, J9225-26, J3315, S0133,
S0165, and Q2020). This study was approved by the
institutional review board.
Statistical analyses
Statistical analyses were conducted using SAS version 9.3
(SAS Institute, Cary, NC), R version 3.0.1 (The R Foun-
dation, Vienna, Austria), and Stata/MP 13.1 (StataCorp,
College Station, TX). Fine and Gray competing risks
regression (20) was used to determine differences in the
risk of prostate cancerespecific mortality (PCSM) between
groups of patients after controlling for age at diagnosis,
year of treatment, and receipt of ADT. For the institutional
cohort, all of whom received brachytherapy, we addition-
ally controlled for receipt of EBRT. In a sensitivity anal-
ysis, we also controlled for duration of ADT received (in
months) when comparing patients with favorable high-risk
disease and unfavorable intermediate-risk disease. We re-
ported estimates of 8-year PCSM in the institutional cohortand 5-year PCSM in the SEER cohort owing to differences
in follow-up. Median values were compared using the
Kruskall-Wallis test, and proportions were compared using
the c2 test or t test, as appropriate. P values were reported
as statistically significant if less than a Z 0.05.
Finally, we conducted 2 sensitivity analyses to test the
possible effect of PSA recording errors on our results.
Patients with discordant values for PSA and PSA inter-
pretation were (1) included in the analyses with their
recorded values or (2) had their PSA level adjusted by a
factor 10 to account for possible misplacement of the
implied decimal point in SEER PSA values (18).
Results
Baseline patient characteristics
In our institutional cohort of 3618 patients, there were 2433
(67.2%) who had unfavorable intermediate-risk disease,
267 (7.4%) who had favorable high-risk disease, and 918
other men (25.4%) who had high-risk disease. Their base-
line characteristics are shown in Table 1. Median follow-up
was 8.4 years (interquartile range, 5.7-11.1 years) in the
entire cohort. Patient demographic characteristics were not
significantly different among the 3 groups. Patients with
favorable high-risk disease were more likely to receive
ADT than those with unfavorable intermediate-risk disease,
and less likely to receive ADT than other men with high-
risk disease (P<.001).
In our validation cohort of 13,275 patients from the
SEER-Medicare database, 6059 (45.6%) had unfavorable
intermediate-risk disease, 1290 (9.7%) had favorable high-
risk disease, and 5926 other men (44.6%) had high-risk
disease. Their baseline characteristics are shown in Table 2.
Favorable high-risk prostate cancer is associated
with relatively low PCSM
Figure 1 and Table 3 show comparisons of PCSM for pa-
tients with unfavorable intermediate-risk, favorable high-
risk, and other high-risk prostate cancer. Patients with
favorable high-risk prostate cancer had a much lower risk
of 8-year PCSM than other patients with high-risk disease
(2.1% vs 7.1%; adjusted hazard ratio [AHR] 0.42; 95%
confidence interval [CI] 0.18-0.996; PZ.049). In contrast,
patients with favorable high-risk prostate cancer had
approximately the same risk of 8-year PCSM as patients
with unfavorable intermediate-risk disease (2.1% vs 2.5%;
AHR 1.17; 95% CI 0.50-2.75; PZ.710).
Results from our nation wide SEER-Medicare validation
cohort are shown in Figure 2 and Table 4. Similar to those in
our derivation cohort, patients with favorable high-risk dis-
ease had a much lower risk of 5-year PCSM than other men
with high-risk disease (1.3% vs 7.2%; AHR 0.21; 95% CI
0.11-0.41; P<.001) and similar 5-year PCSM as those with
unfavorable intermediate-risk disease (1.3% vs 2.0% AHR
Table 1 Baseline patient characteristics for the institutional cohort
Characteristic
Patients
P
Unfavorable
intermediate-risk
(nZ2433)
Favorable high-risk
(nZ267)
Other high-risk
(nZ918)
n % n % n %
Follow-up (y), median (IQR) 8.5 (6.0-11.2) 7.7 (5.6-10.5) 8.1 (5.5-11.1) .049
Year of treatment .019
1997-2005 1523 62.6 146 54.7 546 59.5
2006-2013 910 37.4 121 45.3 372 40.5
Patient age (y) .18
65 581 23.9 52 19.5 202 22.0
>65 1852 76.1 215 80.5 716 78.0
Race .19
White 1510 62.1 173 64.8 602 65.6
Black 213 8.8 26 9.7 69 7.5
Other 143 5.9 7 2.6 50 5.4
Unknown 567 23.3 61 22.8 197 21.5
PSA (ng/mL) <.001
<10 1331 54.7 133 49.8 308 33.6
10-20 1102 45.3 - - 213 23.2
>20 - - 134 50.2 397 43.2
Median PSA (ng/mL) 9.0 20.0 15.2 <.001
Gleason score <.001
6 532 21.9 134 50.2 88 9.6
7 1901 78.1 - - 259 28.2
8 - - 133 49.8 359 39.1
9-10 - - - - 212 23.1
T stage <.001
T1 1331 54.7 267 100.0 248 27.0
T2 1102 45.3 - - 476 51.9
T3 - - - - 194 21.1
Received ADT <.001
No 1674 68.8 146 54.7 302 32.9
Yes 759 31.2 121 45.3 616 67.1
Duration of ADT (y) <.001
<2 2292 94.2 234 87.6 729 79.4
2 12 0.5 2 0.7 47 5.1
Unknown 129 5.3 31 11.6 142 15.5
% Positive biopsies <.001
<50% 813 33.4 183 68.5 372 40.5
50% 1581 65.0 78 29.2 519 56.5
Unknown 39 1.6 6 2.2 27 2.9
Abbreviations: ADT Z androgen deprivation therapy; IQR Z interquartile range.
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determine the possible effects of coding errors of PSA in the
SEER database, when we included 588 patients whose PSA
value and recorded PSA interpretation were discordant, the
hazard ratios changed onlyminimally (favorable high-risk vs
other high-risk: AHR 0.24, P<.001; favorable high-risk vs
unfavorable intermediate-risk: AHR 0.76, PZ.406). When
we adjusted their PSAvalues by a factor of 10 to account for a
possible misplaced decimal point, the hazard ratios were also
similar to those in the original analysis (AHR 0.18, P<.001
and AHR 0.61, PZ.161, respectively).
Finally, although use of long-course ADT was rare in
both cohorts and was similar between the favorable high-risk and unfavorable intermediate-risk groups, we per-
formed a sensitivity analysis adjusting for ADT duration
and confirmed our results demonstrating similar PCSM
between the favorable high-risk and the unfavorable
intermediate-risk groups (institutional cohort: AHR 1.20,
PZ.680; SEER-Medicare cohort: AHR 0.66, PZ.256).Discussion
In this study we defined a subset of patients with “favorable
high-risk prostate cancer” (T1c, Gleason 4 þ 4 Z 8, and
PSA <10 ng/mL or T1c, Gleason 6, and PSA >20 ng/mL)
Table 2 Baseline patient characteristics for the SEER-Medicare cohort
Characteristic
Patients
P
Unfavorable
intermediate-risk
(nZ6059)
Favorable high-risk
(nZ1290)
Other high-risk
(nZ5926)
n % n % n %
Follow-up (y), median (IQR) 2.8 (1.5-4.2) 2.8 (1.5-4.2) 2.8 (1.5-4.1) .003
Year of treatment .947
2004-2006 3119 51.5 653 50.6 3061 51.7
2007-2009 2940 48.5 637 49.4 2865 48.3
Patient age (y) <.001
75 3315 54.7 711 55.1 2985 50.4
>75 2744 45.3 579 44.9 2941 49.6
Race .008
White 4998 82.5 1028 79.7 4757 80.3
Black 636 10.5 169 13.1 714 12.0
Other 425 7.0 93 7.2 455 7.7
PSA (ng/mL) <.001
<10 3492 57.6 852 66.0 2114 35.7
10-20 2567 42.4 - - 1376 23.2
>20 - - 438 34.0 2436 41.1
Median PSA (ng/mL) 8.4 7.9 14.3 <.001
Gleason score <.001
6 189 3.1 438 34.0 282 4.8
7 5870 96.9 - - 1294 21.8
8 - - 852 66.0 2388 40.3
9-10 - - - - 278 4.7
T stage <.001
T1 2725 45.0 1290 100.0 2302 38.8
T2 1102 45.3 - - 3346 56.5
T3 - - - - 278 4.7
Received ADT <.001
No 2351 38.8 382 29.6 917 15.5
Yes 3708 61.2 908 70.4 5009 84.5
Duration of ADT (y) <.001
<2 5685 93.8 1171 90.8 5018 84.7
2 374 6.2 119 9.2 908 15.3
Abbreviations as in Table 1.
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We showed that they have very similar 8-year PCSM
compared with those with unfavorable intermediate-risk9%
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Fig. 1. Prostate cancerespecific mortality for the patients
in the institutional cohort by risk group. The numbers of
patients at risk are shown below the chart.disease: 2.1% and 2.5%, respectively. In competing risks
regression adjusting for age, year of treatment, receipt of
EBRT, and receipt of ADT, there was no significant dif-
ference in PCSM between favorable high-risk and unfa-
vorable intermediate-risk patients (AHR 1.17; PZ.710). In
contrast, patients with favorable high-risk disease had much
lower 8-year PCSM than others with high-risk disease
(2.1% vs 7.1%; AHR 0.42; PZ.049). These findings were
also validated within a large, national cancer database of
radiation-managed patients and were robust to any potential
differences in the duration of ADT received.
These findings suggest that men with favorable high-risk
prostate cancer have significantly better outcomes than
others with high-risk prostate cancer, which might allow for
increased personalization of therapy. This personalization
could be most relevant when determining the appropriate
duration of ADT. Long-course ADT, consisting of 2 to
3 years of androgen suppression, is currently recommended
for all men with high-risk disease by National
Table 3 Prostate cancerespecific mortality (PCSM) at 8 years for patients with unfavorable intermediate-isk, favorable high-risk, and
other high-risk prostate cancer in the institutional cohort
Risk group 8-year PCSM (%) HR (95% CI) P
Unfavorable intermediate-risk disease 2.1
Favorable high-risk disease 2.5
Other high-risk disease 7.1
MVA comparison
Favorable high vs unfavorable intermediate 1.17 (0.50-2.75) .710
Favorable high vs other high 0.42 (0.18-0.996) .049
Unfavorable intermediate vs other high 0.36 (0.23-0.56) <.001
Abbreviations: CI Z confidence interval; HR Z hazard ratio; MVA Z multivariate analysis.
MVA includes adjustment for age, year of treatment, receipt of external beam radiation therapy, and receipt of androgen deprivation therapy.
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of Urology guidelines (1, 2) based on the results of large
randomized trials, including the European Organization for
Research and Treatment of Cancer (EORTC) 22961 trial,
the Radiation Therapy Oncology Group (RTOG) 9202 trial,
and the Grupo de Investigacio´n Clı´nica en Oncologı´a
Radiotera´pica (GICOR) DART 01/05 trial (4-6). All 3 trials
showed improvements in cancer-specific outcomes or
overall survival with long-course ADT compared with
short-course ADT in patients with high-risk prostate cancer.
However, the EORTC and RTOG trials included mostly
patients with locally advanced (T3/T4) prostate cancer and
did not include any patients with nonpalpable (T1c) dis-
ease, which is becoming a more common presentation for
modern high-risk patients. Although the GICOR trial did
include T1c patients, published data from the trial are not
available to determine outcomes for the favorable high-risk
subgroup. Therefore, it is not clear that the benefits of long-
term versus short-term ADT would also apply to the
favorable high-risk cohort identified in this study. Further,
given their low 2.5% risk of PCSM at 8 years using radi-
ation and mainly short-course ADT, the absolute magnitude
of any potential benefit of long-course ADTwould likely be
small and would need to be weighed against the additional
toxicity of longer-duration ADT (8-10).9%
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Fig. 2. Prostate cancerespecific mortality for the patients
in the Surveillance, Epidemiology, and End
ResultseMedicare cohort by risk group. The numbers of
patients at risk are shown below the chart.On the other hand, for intermediate-risk disease, several
trials have established short-course (4-6 months) ADT as
beneficial and sufficient (21-23), and recent work suggests
that this benefit may be limited to those with unfavorable
intermediate-risk disease (14, 24-26). Because of their
similar PCSM in this study, it is possible that patients with
favorable high-risk disease and those with unfavorable
intermediate-risk disease might be adequately treated with
similar hormonal therapy.
Alternatively, one might consider favorable high-risk
patients for treatment with 18 months of ADT given the
preliminary results of a study that failed to prove the su-
periority of 36 months over 18 months of ADT for high-risk
disease, but which has not been fully adopted owing to it
being underpowered as a noninferiority trial (27). Although
only a prospective, randomized, controlled noninferiority
trial can definitively show that the duration of ADT can be
safely shortened in the favorable high-risk subgroup, the
low PCSM rates seen in this group make it unlikely that
there would be a difference in such a trial.
Our findings also have implications for the design of
clinical trials testing the marginal benefit of novel systemic
therapies for men with high-risk disease. Given the low
prostate cancer mortality rate in men with favorable high-
risk disease, such patients are unlikely to significantly
benefit from the addition of novel systemic therapies to
long-term ADT. Therefore, future studies of additional
agents are more likely to be successful if they exclude
patients with favorable high-risk disease in favor of
focusing on other high-risk patients, where a bigger benefit
is likely to be seen.
These results highlight that patients with high-risk
prostate cancer are a heterogeneous group. Other series
that have subclassified patients with high-risk prostate
cancer have focused on surgically managed patients.
Recent data suggest that some patients with pathologic
high-risk disease due to occult extracapsular extension (ie
pT3a) may have better outcomes than those presenting with
clinical T3 disease and similar outcomes as those with
pathologic organ-confined disease (28). Three recent
studies have shown that the presence of fewer high-risk
features may predict for better cancer-specific outcomes
among patients with high-risk prostate cancer treated with
Table 4 Prostate cancerespecific mortality (PCSM) at 5 years for patients with unfavorable intermediate-risk, favorable high-risk,
and other high-risk prostate cancer
Risk group 5-year PCSM (%) HR (95% CI) P
Unfavorable intermediate-risk disease 2.0
Favorable high-risk disease 1.3
Other high-risk disease 7.2
MVA comparison
Favorable high vs unfavorable intermediate 0.67 (0.33-1.36) .268
Favorable high vs other high 0.21 (0.11-0.41) <.001
Unfavorable intermediate vs other high 0.31 (0.23-0.41) <.001
Abbreviations as in Table 3.
MVA includes adjustment for age, year of diagnosis, and receipt of androgen deprivation therapy.
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work, the strengths of our study are that we demonstrate the
presence of a favorable subgroup of high-risk disease
within a radiation-managed cohort and show similar out-
comes between favorable high-risk and unfavorable
intermediate-risk disease. Importantly, unlike prior studies,
our findings might be applied to personalize therapy for
radiation-managed patients with favorable high-risk dis-
ease, particularly with regard to the duration of ADT to be
used.
There are some potential limitations to our study. First,
our results suggesting similar PCSM between patients with
favorable high-risk and unfavorable intermediate-risk
prostate cancer are based on retrospective data and there-
fore should be interpreted cautiously. We attempted to
control for differences in treatment between the 2 groups,
including duration of ADT, but it is possible that a third
factor is responsible for the similar PCSM of these 2 groups
of patients. Only a large randomized trial can account for
all possible sources of selection bias.
Second, our classification system might not apply at the
extremes of presentation. For example, a very young patient
with favorable high-risk disease but 12 of 12 biopsy cores
positive with nearly 100% involvement of each core would
likely require aggressive therapy, including long-course
ADT, owing to their relatively poor prognosis and long life
expectancy. Therefore, clinical judgement should be exer-
cised when applying our results.
Third, our derivation cohort consisted of patients treated
at a single institution specializing in brachytherapy, which
may represent a biased sample of radiation-managed pa-
tients. We attempted to address this limitation by validating
our initial findings in a more general national cohort from
the SEER-Medicare database and found very similar
results.
Fourth, our validation cohort depended on the recorded
values of PSA in the SEER database, which may contain a
number of errors (18), possibly due to misplacement of an
implied decimal point. However, in preliminary in-
vestigations by the SEER program, only 5% of PSA
values led to incorrect classification of PSA among the 3
categories of values relevant to the present study
(<10 ng/mL, 10-20 ng/mL, and >20 ng/mL) (17). Basedon the observations in a recent quality analysis of the
SEER database (19), we tried to account for this possible
source of error by excluding patients who had discordant
PSA values and recorded PSA interpretations (eg, PSA
<4 ng/mL recorded as “positive/elevated,” 4.2% of our
initial cohort). In addition, we conducted sensitivity
analyses in which these originally excluded patients were
included in the analysis with or without adjustment for a
presumed misplacement of the implied decimal point.
Though our approach likely did not account for all
possible errors in the SEER dataset, we observed similar
results in the sensitivity analyses as in our main analysis.
Although our results should be interpreted with caution
given the possibility of erroneous data points, the low rate
of incorrect categorization of PSA values combined with
the results of our sensitivity analyses may be interpreted
to support the validity of our findings.
Fifth, it is possible that there is a true, clinically sig-
nificant difference in the risk of PCSM between patients
with unfavorable intermediate-risk or favorable high-risk
disease, but that we failed to detect it owing to inadequate
power. This possibility is not likely given that our valida-
tion cohort had 13,275 patients and that the estimated
adjusted hazard ratio was <1 (favoring patients with
favorable high-risk disease) in that cohort.Conclusion
Patients with favorable high-risk disease (T1c, Gleason
4 þ 4 Z 8, and PSA <10 ng/mL or T1c, Gleason 6, and
PSA >20 ng/mL) have significantly better PCSM than
other patients with high-risk disease and similar PCSM as
those with unfavorable intermediate-risk disease. This new
classification system may allow for personalization of
treatment within high-risk disease.References
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